Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27113 Page 1 of
`28
`
`EXHIBIT 16
`
`EXHIBIT 16 - Page 186
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27114 Page 2 of
`28
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`WILSON SONSINI GOODRICH & ROSATI P.C.
`PAUL D. TRIPODI II (SBN 162380)
`ptripodi@wsgr.com
`WENDY L. DEVINE (SBN 246337)
`wdevine@wsgr.com
`NATALIE J. MORGAN (SBN 211143)
`nmorgan@wsgr.com
`633 West Fifth Street, Suite 1550
`Los Angeles, CA 90071
`Telephone: 323-210-2900
`Fax: 866-974-7329
`Hilgers Graben PLLC
`MICHAEL T. HILGERS (Pro Hac Vice)
`mhilgers@hilgersgraben.com
`575 Fallbrook Blvd, Suite 202
`Lincoln, NE 68521
`Telephone: 402-218-2106
`Fax: 402-413-1880
`
`Attorneys for Plaintiff NuVasive, Inc.
`
`UNITED STATES DISTRICT COURT
`SOUTHERN DISTRICT OF CALIFORNIA – SAN DIEGO DIVISION
`Case No. 18-cv-00347-CAB-MDD
`NUVASIVE, INC., a Delaware
`corporation,
` Plaintiff,
`v.
`
`PLAINTIFF NUVASIVE, INC.’S
`SUPPLEMENTAL RESPONSES
`TO DEFENDANTS’
`INTERROGATORY NOS. 1-7
`AND 9-16 (IMPLANT PATENT
`PHASE)
`Judge: Cathy A. Bencivengo
`
`ALPHATEC HOLDINGS, INC., a
`Delaware corporation, and ALPHATEC
`SPINE, INC., a California corporation,
` Defendants.
`
`NUVASIVE’S SUPP. RESPONSES TO
`DEFS’ INTERROGATORIES
`(NOS. 1-7 & 9-16)
`
`18-cv-00347-CAB-MDD
`
`EXHIBIT 16 - Page 187
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27115 Page 3 of
`28
`
`Pursuant to Rule 26 and 33 of the Federal Rules of Civil Procedure, Plaintiff
`NuVasive, Inc. (“NuVasive”), by and through its undersigned counsel, hereby
`responds to Defendants Alphatec Holdings, Inc. and Alphatec Spine, Inc.’s
`(collectively “Alphatec” or “Defendants”) First Set of Interrogatories (Nos. 1 – 7
`and 9 – 12) and Second Set of Interrogatories (Nos. 13 - 15) and Third Set of
`Interrogatories (No. 16) as follows:
`GENERAL OBJECTIONS
`In addition to any specifically stated objections, NuVasive’s responses
`herein are subject to and incorporate the following general objections:
`1.
`NuVasive asserts each of the following General Objections and
`expressly incorporates them into each response set forth below. By providing a
`response to any interrogatory, NuVasive does not waive or otherwise limit these
`General Objections. Furthermore, reference to any of these General Objections in
`any specific response shall not waive or otherwise limit the applicability of all of
`these General Objections to each and every response.
`2.
`NuVasive objects to all definitions, instructions, and interrogatories to
`the extent that they are unduly burdensome and oppressive, overly broad, vague,
`ambiguous and/or to the extent they are inconsistent with and/or seek to impose
`upon NuVasive obligations beyond those required by the Federal Rules of Civil
`Procedure, the Local Rules of the United States District Court for the Southern
`District of California, or any Court Order in this matter, including this Court’s
`Scheduling Order. In responding to these interrogatories, NuVasive will only
`comply with the obligations imposed on it by the Federal Rules of Civil Procedure,
`the Local Rules of the United States District Court for the Southern District of
`California, any applicable orders of this Court, and any stipulation or agreement
`between the parties.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28 NUVASIVE’S SUPP. RESPONSES TO
`DEFS’ INTERROGATORIES
`(NOS. 1-7 & 9-16)
`
`1
`
`18-cv-00347-MDD-CAB
`
`EXHIBIT 16 - Page 188
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27116 Page 4 of
`28
`
`(cid:120) DHF-10-005 (re implants): NUVA_ATEC0181087 –
`NUVA_ATEC0181097;
`(cid:120) DHF-10-009 (re access system): NUVA_ATEC0182802 –
`NUVA_ATEC0183485;
`(cid:120) DHF-11-012 (re implants): NUVA_ATEC0190887 –
`NUVA_ATEC0190950;
`(cid:120) DHF-11-013 (re implants): NUVA_ATEC0181098 –
`NUVA_ATEC0181916;
`(cid:120) DHF-11-017 (re implants): NUVA_ATEC0181917 –
`NUVA_ATEC0182500;
`(cid:120) DHF-13-002 (re shims and XLIF kit components): NUVA_ATEC0182501 –
`NUVA_ATEC0182515;
`(cid:120) DHF-14-001 (re implants): NUVA_ATEC0182516 –
`NUVA_ATEC0182801;
`(cid:120) DHF-14-020 (re dilators): NUVA_ATEC0012927 –
`NUVA_ATEC0012935.
`Discovery is ongoing and NuVasive reserves its right to amend or
`supplement its response to this interrogatory.
`THIRD SUPPLEMENTAL RESPONSE TO INTERROGATORY NO. 2:
`Pursuant to the Court’s scheduling order (Doc. No. 293), NuVasive affirms
`its prior response and confirms it has no new information to supplement at this
`time.
`INTERROGATORY NO. 3:
`For each asserted claim of the patents-in-suit, describe in detail the facts and
`circumstances relating to the first written description, offer for sale, sale, public
`disclosure, public use, or disclosure to any person other than a named inventor of
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28 NUVASIVE’S SUPP. RESPONSES TO
`DEFS’ INTERROGATORIES
`(NOS. 1-7 & 9-16)
`
`27
`
`18-cv-00347-MDD-CAB
`
`EXHIBIT 16 - Page 189
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27117 Page 5 of
`28
`
`the claimed invention, including, without limitation, the identities of the persons
`involved in each such event, the identities of the persons most knowledgeable
`regarding each such event, the date on which each such event occurred, and the
`identification of each document that reflects or relates to such facts and
`circumstances.
`RESPONSE TO INTERROGATORY NO. 3:
`NuVasive incorporates by reference each of the General Objections.
`NuVasive objects to this interrogatory on the grounds that it contains at least three
`discrete subparts, is compound, and constitutes at least three interrogatories.
`NuVasive objects to this interrogatory as vague and ambiguous with respect to the
`term “the circumstances.” NuVasive objects to this interrogatory on the grounds
`and to the extent it is overly broad, unduly burdensome, not proportional to the
`needs of the case, and not relevant to any claim or defense in this case.
`Specifically, NuVasive objects to the interrogatory to the extent it calls for
`NuVasive to “describe in detail” the circumstances relating to the first descriptions,
`disclosures and sales of the claimed inventions. NuVasive objects to this
`interrogatory to the extent it seeks “Privileged Information.” NuVasive objects to
`this interrogatory to the extent it calls for legal conclusions. NuVasive objects to
`this interrogatory to the extent it attempts the shift the burden of proof regarding
`invalidity to NuVasive. NuVasive objects to this interrogatory to the extent it seeks
`information no longer in NuVasive’s possession, custody, or control.
`Subject to and without waiving the foregoing objections, NuVasive responds
`as follows: the first written description for each of the patents-in-suit is at least as
`early as the earliest priority date of the respective patent-in-suit based on the
`earliest filed parent patent application.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28 NUVASIVE’S SUPP. RESPONSES TO
`DEFS’ INTERROGATORIES
`(NOS. 1-7 & 9-16)
`
`28
`
`18-cv-00347-MDD-CAB
`
`EXHIBIT 16 - Page 190
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27118 Page 6 of
`28
`
`Additionally, Alphatec has admitted that NuVasive’s “eXtreme Lateral
`Interbody Fusion” product (or “XLIF”), which includes the MaXcess access
`system and CoRoent XL implants, embodies the asserted claims of the patents-in-
`suit. Doc. No. 48 at 16. Based on information available to NuVasive at this time,
`NuVasive states that it launched aspects of XLIF in October 2003 at the North
`American Spine Society (NASS) Annual Meeting, including its MaXcess access
`system, and specifically MaXcess I. Persons involved in this this launch include
`Pat Miles, Eric Finley, and Scot Martinelli. In addition, MaXcess III launched on
`September 12, 2006, and MaXcess III Solid launched on November 13, 2008.
`In October 2004, at NASS, NuVasive launched the CoRoent XL implant as
`part of XLIF. The persons involved in the launch of CoRoent XL are Matthew
`Curran, Matthew Copp, Scot Martinelli, Patrick Miles, and David Ivanko.
`In addition, pursuant to Local Patent Rule 3.2(b) and Fed. R. Civ. P. 33(d),
`NuVasive further states that it will produce and has produced non-privileged
`documents from which the information requested can be ascertained, including
`documents bearing the following Bates numbers:
`NUVA_ATEC0000001 – NUVA_ATEC0000290;
`NUVA_ATEC0000544 – NUVA_ATEC0014446;
`NUVA_ATEC0014504 – NUVA_ATEC0015487;
`NUVA_ATEC0016164 – NUVA_ATEC0016948;
`NUVA_ATEC0016949 – NUVA_ATEC0039458;
`NUVA_ATEC0039459 – NUVA_ATEC0040421;
`Discovery is ongoing and NuVasive reserves its right to amend or
`supplement its response to this interrogatory.
`SUPPLEMENTAL RESPONSE TO INTERROGATORY NO. 3:
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28 NUVASIVE’S SUPP. RESPONSES TO
`DEFS’ INTERROGATORIES
`(NOS. 1-7 & 9-16)
`
`29
`
`18-cv-00347-MDD-CAB
`
`EXHIBIT 16 - Page 191
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27119 Page 7 of
`28
`
`In addition to its previously asserted General and Specific Objections,
`NuVasive continues to object that this interrogatory is overly broad, unduly
`burdensome, and not proportional to the needs of the case because it seeks a
`“detailed” description of information spanning nearly two decades that is no longer
`readily accessible to NuVasive due to the passage of time and relevant personnel
`departing the company over the intervening 15-plus years. In light of this,
`NuVasive maintains that its previous response and citation to documents pursuant
`to Fed. R. Civ. P. 33(d) is proper at least because the burden of deriving the
`requested information would be substantially the same for either NuVasive or
`Alphatec.
`Subject to and without waiving the foregoing objections, NuVasive further
`states: Based on a reasonable investigation of information from the personal
`knowledge of those relevant persons still at or employed by NuVasive to date,
`NuVasive has not identified a disclosure earlier than those provided in its prior
`response. Additional persons who may have knowledge regarding the 2004 launch
`and the earliest use and sale of the embodying CoRoent XL implant, include Ryan
`Donahoe.
`In addition, pursuant to Fed. R. Civ. P. 33(d), NuVasive has produced and
`will produce non-privileged documents from which the information regarding the
`launches, and earliest disclosure, use, and sale of the inventions of the asserted
`claims of the patents-in-suit, can be ascertained, including documents bearing the
`following Bates numbers:
`(cid:120) NUVA_ATEC0115139 – NUVA_ATEC0115153;
`(cid:120) NUVA_ATEC0040546 – NUVA_ATEC0040573;
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28 NUVASIVE’S SUPP. RESPONSES TO
`DEFS’ INTERROGATORIES
`(NOS. 1-7 & 9-16)
`
`30
`
`18-cv-00347-MDD-CAB
`
`EXHIBIT 16 - Page 192
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27120 Page 8 of
`28
`
`(cid:120) NUVA_ATEC0000001 – NUVA_ATEC0000290,
`NUVA_ATEC0014504 – NUVA_ATEC0015487,
`NUVA_ATEC0016164 – NUVA_ATEC0016948;
`(cid:120) NUVA_ATEC0016949 – NUVA_ATEC0039458,
`NUVA_ATEC0039459 – NUVA_ATEC0040421
`Finally, NuVasive’s Design History Files (“DHF”) for the various versions
`of the embodying components of XLIF (including the MaXcess I access system
`and CoRoent XL implant) contain NuVasive’s contemporaneous business records
`and documentation regarding, inter alia, the launch of such components, and
`include detailed information responsive to this interrogatory. The specific DHF
`documents produced as kept in NuVasive’s ordinary course of business and cited
`above are:
`(cid:120) DHF-01-002 (re dilators): NUVA_ATEC0000544 –
`NUVA_ATEC0009120, NUVA_ATEC0012840 –
`NUVA_ATEC0012926;
`(cid:120) DHF-02-006 (re access system): NUVA_ATEC0009121 –
`NUVA_ATEC0009814, NUVA_ATEC0012463 –
`NUVA_ATEC0012465, NUVA_ATEC0012618 –
`NUVA_ATEC0012620;
`(cid:120) DHF-03-003 (re implants): NUVA_ATEC0009815 –
`NUVA_ATEC0010067, NUVA_ATEC0012542 –
`NUVA_ATEC0012597;
`(cid:120) DHF-04-002 (re dilators); NUVA_ATEC0010068 –
`NUVA_ATEC0010509;
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28 NUVASIVE’S SUPP. RESPONSES TO
`DEFS’ INTERROGATORIES
`(NOS. 1-7 & 9-16)
`
`31
`
`18-cv-00347-MDD-CAB
`
`EXHIBIT 16 - Page 193
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27121 Page 9 of
`28
`
`(cid:120) DHF-04-004 (re light cables): NUVA_ATEC0010510 –
`NUVA_ATEC0011052, NUVA_ATEC0012430 –
`NUVA_ATEC0012462;
`(cid:120) DHF-06-008 (re shims and XLIF kit components):
`NUVA_ATEC0011053 – NUVA_ATEC0012429,
`NUVA_ATEC0012466 – NUVA_ATEC0012541,
`NUVA_ATEC0012598 – NUVA_ATEC0012617,
`NUVA_ATEC0012621 – NUVA_ATEC0012839,
`NUVA_ATEC0012936 – NUVA_ATEC0012952;
`(cid:120) DHF-06-018 (re dilators): NUVA_ATEC0014000 –
`NUVA_ATEC0014446;
`(cid:120) DHF-08-012 (re shims and XLIF kit components):
`NUVA_ATEC13829 – NUVA_ATEC0013999;
`(cid:120) DHF-09-020 (re access system): NUVA_ATEC0012953 –
`NUVA_ATEC0013828;
`(cid:120) DHF-14-020 (re dilators): NUVA_ATEC0012927 –
`NUVA_ATEC0012935.
`Discovery is ongoing and NuVasive reserves its right to amend or
`supplement its response to this interrogatory.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28 NUVASIVE’S SUPP. RESPONSES TO
`DEFS’ INTERROGATORIES
`(NOS. 1-7 & 9-16)
`
`SECOND SUPPLEMENTAL RESPONSE TO INTERROGATORY NO. 3:
`Subject to and without waiving the foregoing objections, NuVasive further
`states: NuVasive hereby amends its prior response relating to its DHFs regarding
`the various embodying components of XLIF. The relevant DHF documents
`regarding the various embodying components of XLIF produced as kept in
`NuVasive’s ordinary course of business are:
`
`32
`
`18-cv-00347-MDD-CAB
`
`EXHIBIT 16 - Page 194
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27122 Page 10 of
`28
`
`(cid:120) DHF-01-002 (re dilators): NUVA_ATEC0000544 –
`NUVA_ATEC0009120, NUVA_ATEC0012840 – NUVA_ATEC0012926;
`(cid:120) DHF-02-006 (re access system): NUVA_ATEC0009121 –
`NUVA_ATEC0009814, NUVA_ATEC0012463 – NUVA_ATEC0012465,
`NUVA_ATEC0012618 – NUVA_ATEC0012620, NUVA_ATEC0183486 –
`NUVA_ATEC0183512;
`(cid:120) DHF-03-001 (re dilators and XLIF kit components): NUVA_ATEC0183513
`– NUVA_ATEC0184007;
`(cid:120) DHF-03-003F & DHF-03-003L (re implants): NUVA_ATEC0184008 –
`NUVA_ATEC0187064;
`(cid:120) DHF-04-002 (re dilators); NUVA_ATEC0010068 –
`NUVA_ATEC0010509;
`(cid:120) DHF-04-004 (re light cables): NUVA_ATEC0010510 –
`NUVA_ATEC0011052, NUVA_ATEC0012430 – NUVA_ATEC0012462;
`(cid:120) DHF-06-008 (re shims and XLIF kit components): NUVA_ATEC0011053 –
`NUVA_ATEC0012429, NUVA_ATEC0012466 – NUVA_ATEC0012541,
`NUVA_ATEC0012598 – NUVA_ATEC0012617,
`NUVA_ATEC0012621 – NUVA_ATEC0012839, NUVA_ATEC0012936 –
`NUVA_ATEC0012952;
`(cid:120) DHF-06-018 (re dilators): NUVA_ATEC0014000 – NUVA_ATEC0014446;
`(cid:120) DHF-07-012 (re dilators and XLIF kit components): NUVA_ATEC0187065
`– NUVA_ATEC0188377;
`(cid:120) DHF-08-012 (re shims and XLIF kit components): NUVA_ATEC13829 –
`NUVA_ATEC0013999;
`(cid:120) DHF-08-016 (re implants): NUVA_ATEC0180896 – NUVA_ATEC0181086;
`(cid:120) DHF-09-003 (re dilators): NUVA_ATEC0188378 – NUVA_ATEC0190886;
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28 NUVASIVE’S SUPP. RESPONSES TO
`DEFS’ INTERROGATORIES
`(NOS. 1-7 & 9-16)
`
`33
`
`18-cv-00347-MDD-CAB
`
`EXHIBIT 16 - Page 195
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27123 Page 11 of
`28
`
`(cid:120) DHF-09-020 (re access system): NUVA_ATEC0012953 –
`NUVA_ATEC0013828;
`(cid:120) DHF-10-005 (re implants): NUVA_ATEC0181087 – NUVA_ATEC0181097;
`(cid:120) DHF-10-009 (re access system): NUVA_ATEC0182802 –
`NUVA_ATEC0183485;
`(cid:120) DHF-11-012 (re implants): NUVA_ATEC0190887 – NUVA_ATEC0190950;
`(cid:120) DHF-11-013 (re implants): NUVA_ATEC0181098 – NUVA_ATEC0181916;
`(cid:120) DHF-11-017 (re implants): NUVA_ATEC0181917 – NUVA_ATEC0182500;
`(cid:120) DHF-13-002 (re shims and XLIF kit components): NUVA_ATEC0182501 –
`NUVA_ATEC0182515;
`(cid:120) DHF-14-001 (re implants): NUVA_ATEC0182516 – NUVA_ATEC0182801;
`(cid:120) DHF-14-020 (re dilators): NUVA_ATEC0012927 – NUVA_ATEC0012935.
`Discovery is ongoing and NuVasive reserves its right to amend or supplement its
`response to this interrogatory.
`THIRD SUPPLEMENTAL RESPONSE TO INTERROGATORY NO. 3:
`Pursuant to the Court’s scheduling order (Doc. No. 293), NuVasive affirms
`its prior response and confirms it has no new information to supplement at this
`time.
`INTERROGATORY NO. 4:
`For each of the patents-in-suit, provide all facts and identify all
`corroborating documents regarding the ownership of any right, title, or interest in
`or to each patent, including identifying the entity that currently owns the right,
`title, or interest; a full explanation of the chain of title to any and all rights, title, or
`interests in or to each patent; and the circumstances regarding each entity’s
`assignment/acquisition of any right, title, or interest in each of the patents-in-suit
`(including, without limitation, the reasons for assignment; dates of acquisition;
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28 NUVASIVE’S SUPP. RESPONSES TO
`DEFS’ INTERROGATORIES
`(NOS. 1-7 & 9-16)
`
`34
`
`18-cv-00347-MDD-CAB
`
`EXHIBIT 16 - Page 196
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27124 Page 12 of
`28
`
`NuVasive states that the contentions and facts it intends to rely upon to
`support its claim that it is entitled to a reasonable royalty for Alphatec’s
`infringement of the implant patents-in-suit are set forth in the following
`documents, in addition to those previously identified in NuVasive’s responses to
`this interrogatory:
`1. Expert Report of Blake Inglish, dated November 1, 2019, including all
`cited exhibits;
`2. Expert Report of Blake Inglish, dated November 8, 2019, pgs. 10 and
`118-206, including all cited exhibits;
`3. Expert Report of Dr. Jim Youssef, dated November 1, 2019, including
`all cited exhibits;
`a. Exhibits A-G
`b. Appendices A-G
`c. ¶¶ 61-104
`d. ¶¶ 120-1328
`e. ¶¶ 1368-1381
`4. Expert Report of Dr. Jim Youssef, dated November 8, 2019, pgs. 1-
`17, including all cited exhibits.
`a. ¶¶ 1-30
`NuVasive states that discovery is ongoing and that, to the extent NuVasive’s
`experts have not yet offered their full opinion regarding a reasonable royalty
`related to the implant patents-in-suit, NuVasive reserves the right to disclose and
`rely on additional expert reports, as contemplated by the parties’ Joint Discovery
`Plan (Doc. 292).
`INTERROGATORY NO. 13:
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28 NUVASIVE’S SUPP. RESPONSES TO
`DEFS’ INTERROGATORIES
`(NOS. 1-7 & 9-16)
`
`135
`
`18-cv-00347-MDD-CAB
`
`EXHIBIT 16 - Page 197
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27125 Page 13 of
`28
`
`Identify each product that NuVasive contends embodies any asserted claims
`of the patents-in-suit and/or competes with any accused product, including, for
`NuVasive products, identification of each asserted claim NuVasive contends is
`embodied by each such product and the first (1) description in print, (2) offer for
`sale, (3) sale, (4) public disclosure, and (5) use of each such product; and for each
`non-NuVasive product, identification of NuVasive’s first (1) awareness, (2)
`knowledge of any offers for sale, (3) knowledge of any sales, and (4) knowledge of
`any use of each such product.
`RESPONSE TO INTERROGATORY NO. 13:
`NuVasive incorporates by reference each of the General Objections.
`NuVasive objects to this interrogatory on the grounds that it contains at least nine
`discrete subparts, is compound, and constitutes at least nine interrogatories.
`NuVasive objects to this interrogatory as vague and ambiguous with respect to the
`terms “competes with,” “identification,” “NuVasive’s first awareness,”
`“NuVasive’s first knowledge,” and “any use.” NuVasive objects to this
`interrogatory on the grounds and to the extent it is overly broad, unduly
`burdensome, not proportional to the needs of the case, and not relevant to any
`claim or defense in this case. Specifically, NuVasive objects to this interrogatory to
`the extent it seeks information concerning third-party products. Relatedly, with
`respect to the “Accused Products,” this interrogatory seeks information that is
`duplicative of the information set forth in NuVasive’s Disclosure of Asserted
`Claims and Infringement Contentions; to the extent this interrogatory seeks
`information beyond such duplicative information, this interrogatory seeks
`information that is overbroad, not relevant to any claim or defense in this case, and
`is not proportional to the needs of this case. NuVasive will respond to this
`interrogatory to the extent it seeks information regarding NuVasive’s products. For
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28 NUVASIVE’S SUPP. RESPONSES TO
`DEFS’ INTERROGATORIES
`(NOS. 1-7 & 9-16)
`
`136
`
`18-cv-00347-MDD-CAB
`
`EXHIBIT 16 - Page 198
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27126 Page 14 of
`28
`
`similar reasons, NuVasive objects to this interrogatory to the extent it seeks
`information regarding various “first” activities to the extent such activities cannot
`constitute prior art to any of the patents-in-suit. NuVasive also objects to this
`interrogatory because it is unlimited as to time. NuVasive objects to this
`interrogatory to the extent it seeks “Privileged Information.” NuVasive objects to
`this interrogatory to the extent it calls for legal conclusions. NuVasive objects to
`this interrogatory to the extent it seeks information that is not and/or is no longer in
`NuVasive’s possession, custody, or control. NuVasive objects to this interrogatory
`to the extent it seeks information that is publicly available and/or equally available
`to Alphatec and NuVasive, and is therefore as easily obtainable by Alphatec as
`NuVasive. NuVasive objects to this interrogatory to the extent it seeks information
`duplicative of the information sought in Alphatec’s Interrogatory No. 3. NuVasive
`objects to this interrogatory as premature to the extent it seeks expert testimony.
`NuVasive will provide expert reports with its positions regarding Alphatec’s
`infringement of the asserted claims of the patents-in-suit and NuVasive’s products’
`embodiment of the asserted claims of the patents-in-suit at the time set forth in the
`Court’s scheduling order.
`Subject to and without waiving the foregoing objections, NuVasive responds
`as follows: NuVasive incorporates by reference its Complaint (Doc. No. 1), its
`Memorandum of Points and Authorities in Support of Motion for Preliminary
`Injunction (Doc. No. 37-1), the Declaration of Jim A. Youssef, M.D., in Support of
`NuVasive’s Motion for Preliminary Injunction (Doc. No. 37-45), NuVasive’s
`Reply in Support of its Motion for Preliminary Injunction (Doc. No. 77), the Reply
`Declaration of Jim A. Youssef, M.D. in Support of NuVasive’s Motion for
`Preliminary Injunction (Doc. No. 77-56), and the Reply Declaration of Matthew
`Link in Support of NuVasive’s Motion for Preliminary Injunction (Doc. No. 77-
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28 NUVASIVE’S SUPP. RESPONSES TO
`DEFS’ INTERROGATORIES
`(NOS. 1-7 & 9-16)
`
`137
`
`18-cv-00347-MDD-CAB
`
`EXHIBIT 16 - Page 199
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27127 Page 15 of
`28
`
`52). In addition, NuVasive states the following based on its knowledge and
`information collected to date:
`XLIF
`NuVasive states that various components and versions of its “eXtreme
`Lateral Interbody Fusion” product (or “XLIF”), which includes the MaXcess
`access system and CoRoent XL implants, or their use embody the asserted claims
`of the patents-in-suit, and further notes that Alphatec has admitted that XLIF
`embodies the asserted claims of the patents-in-suit. Doc. No. 48 at 16. NuVasive
`further incorporates by reference its Disclosure of Asserted Claims and
`Infringement Contentions, which identifies the XLIF components or the use
`thereof that embody the asserted claims of the patents-in-suit. NuVasive also
`incorporates by reference its response to Alphatec’s Interrogatory No. 3 (and all
`supplements thereto), which sets forth the dates various components of XLIF were
`launched.
`In addition, pursuant to Local Patent Rule 3.2(b) and Fed. R. Civ. P. 33(d),
`NuVasive states it will produce and has produced non-privileged documents from
`which the information requested with respect to XLIF can be ascertained,
`including documents bearing the following Bates numbers:
`NUVA_ATEC0000544 – NUVA_ATEC0014446;
`NUVA_ATEC0015491 – NUVA_ATEC0015614;
`NUVA_ATEC0040546 – NUVA_ATEC0040644.
`The Accused Products
`NuVasive incorporates by reference its Disclosure of Asserted Claims and
`Infringement Contentions, which identifies the components of Alphatec’s Battalion
`Lateral System with Squadron Lateral Retractor (“the Accused Products”) or the
`use thereof that infringe the asserted claims of the patents-in-suit. Additionally,
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28 NUVASIVE’S SUPP. RESPONSES TO
`DEFS’ INTERROGATORIES
`(NOS. 1-7 & 9-16)
`
`138
`
`18-cv-00347-MDD-CAB
`
`EXHIBIT 16 - Page 200
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27128 Page 16 of
`28
`
`based on information available to NuVasive at this time, NuVasive states that it is
`aware that the Accused Products were launched on a limited basis in April 2017,
`and were fully commercially launched in October 2017.
`Discovery is ongoing and NuVasive reserves its right to amend or
`supplement its response to this interrogatory.
`SUPPLEMENTAL RESPONSE TO INTERROGATORY NO. 13:
`In addition to its previously asserted General and Specific Objections,
`NuVasive continues to object that this interrogatory is overly broad, unduly
`burdensome, and not proportional to the needs of the case because it seeks
`identification of information from up to nearly two decades ago that is no longer
`readily accessible to NuVasive due to the passage of time and relevant personnel
`departing the company over the intervening 15-plus years. Relatedly, NuVasive
`also objects that this interrogatory seeks information, including third party
`products, not readily or reasonably available to NuVasive. In light of this,
`NuVasive maintains that its previous response and citation to documents pursuant
`to Fed. R. Civ. P. 33(d) is proper at least because the burden of deriving the
`requested information would be substantially the same for either NuVasive or
`Alphatec.
`Subject to and without waiving the foregoing objections, NuVasive further
`states: NuVasive’s contentions and facts it intends to rely upon to support its
`contentions regarding embodying and competitor products that are contained
`within NuVasive’s Complaint (Doc. No. 1), its Memorandum of Points and
`Authorities in Support of Motion for Preliminary Injunction (Doc. No. 37-1), the
`Declaration of Jim A. Youssef, M.D. in Support of NuVasive’s Motion for
`Preliminary Injunction (Doc. No. 37-45), NuVasive’s Reply in Support of its
`Motion for Preliminary Injunction (Doc. No. 77), the Reply Declaration of Jim A.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28 NUVASIVE’S SUPP. RESPONSES TO
`DEFS’ INTERROGATORIES
`(NOS. 1-7 & 9-16)
`
`139
`
`18-cv-00347-MDD-CAB
`
`EXHIBIT 16 - Page 201
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27129 Page 17 of
`28
`
`Youssef, M.D. in Support of NuVasive’s Motion for Preliminary Injunction (Doc.
`No. 77-56), and the Reply Declaration of Matthew Link in Support of NuVasive’s
`Motion for Preliminary Injunction (Doc. No. 77-52) are set forth in the following
`portions of these documents:
`1. Complaint (Doc. No. 1)
`(cid:120) ¶¶ 18-25, 43-113, 114-138, 140-497.
`(cid:120) Exs. D, E, U, V
`2. Memorandum of Points and Authorities in Support of Motion for
`Preliminary Injunction (Doc. No. 37-1)
`(cid:120) Pgs. 3-4, 7-12 (Doc. No. 37-1 at 8-9, 12-17)
`3. Declaration of Jim A. Youssef, M.D., in Support of NuVasive’s Motion
`for Preliminary Injunction (Doc. No. 37-45)
`(cid:120) ¶¶ 40-56, 58, 79-367
`(cid:120) Exs. V, W
`(cid:120) Appendices A-F
`4. Reply in Support of NuVasive’s Motion for Preliminary Injunction (Doc.
`No. 77)
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28 NUVASIVE’S SUPP. RESPONSES TO
`DEFS’ INTERROGATORIES
`(NOS. 1-7 & 9-16)
`
`(cid:120) Pgs. 1-5, 8-9 (Doc. No. 77 at 7-11, 14-15)
`5. Reply Declaration of Jim A. Youssef, M.D. in Support of NuVasive’s
`Motion for Preliminary Injunction (Doc. No. 77-56)
`(cid:120) ¶¶ 41-42, 48, 50-51, 58-182, 393-394, and accompanying exhibits and
`citations
`(cid:120) Appendices G-L
`6. Reply Declaration of Matthew Link in Support of NuVasive’s Motion for
`Preliminary Injunction (Doc. No. 77-52)
`(cid:120) ¶¶ 57-68, and accompanying exhibits and citations
`
`140
`
`18-cv-00347-MDD-CAB
`
`EXHIBIT 16 - Page 202
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27130 Page 18 of
`28
`
`In addition, NuVasive states the following:
`XLIF
`The following components of XLIF, or their use, embody the asserted claims
`of the patents-in-suit:
`U.S. Patent No. 7,819,801:
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28 NUVASIVE’S SUPP. RESPONSES TO
`DEFS’ INTERROGATORIES
`(NOS. 1-7 & 9-16)
`
`141
`
`18-cv-00347-MDD-CAB
`
`EXHIBIT 16 - Page 203
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27131 Page 19 of
`28
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28 NUVASIVE’S SUPP. RESPONSES TO
`DEFS’ INTERROGATORIES
`(NOS. 1-7 & 9-16)
`
`142
`
`18-cv-00347-MDD-CAB
`
`EXHIBIT 16 - Page 204
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27132 Page 20 of
`28
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28 NUVASIVE’S SUPP. RESPONSES TO
`DEFS’ INTERROGATORIES
`(NOS. 1-7 & 9-16)
`
`143
`
`18-cv-00347-MDD-CAB
`
`EXHIBIT 16 - Page 205
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27133 Page 21 of
`28
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28 NUVASIVE’S SUPP. RESPONSES TO
`DEFS’ INTERROGATORIES
`(NOS. 1-7 & 9-16)
`
`144
`
`18-cv-00347-MDD-CAB
`
`EXHIBIT 16 - Page 206
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 300-17 Filed 01/08/21 PageID.27134 Page 22 of
`28
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28 NUVASIVE’S SUPP. RESPONSES TO
`DEFS’ INTERROGATORIES
`(NOS. 1-7 & 9-16)
`
`In addition, based on a reasonable investigation to date, including an
`investigation of information from the personal knowledge of those relevant persons
`still at or employed by NuVasive, NuVasive further states:
`NuVasive launched aspects of XLIF in October 2003 at the North American
`Spine Society (NASS) Annual Meeting, including its MaXcess access system, and
`specifically MaXcess I. Persons involved in this launch include Pat Miles, Eric
`Finley, and Scot Martinelli. In addition, MaXcess II Solid launched at NASS 2004,
`MaXcess II launched on August 29, 2005, MaXcess III launched on September 12,
`2006, MaXcess III Solid launched on November 13, 2008, and MaXcess 4
`launched on April 29, 2011. NuVasive further identifies Eric Finley as a current
`NuVasive employee that may have knowledge regarding the launch of the
`MaXcess I and II access systems.
`In October 2004, at NASS, NuVasive launched the CoRoent XL implant as
`a part of XLIF. The persons involved in the launch of CoRoent XL are Matthew
`Curran, Matthew Copp, Scot Martinelli, Patrick Miles, and David Ivanko. In
`addition, CoRoent XL-CT launched in 2008